Screener
ImmunityBio, Inc. IBRX Reportable Segment — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total research and development expense (including amounts with related parties) | 67,989 | 48,234 |
| Selling, general and administrative (including amounts with related parties) | 45,770 | 32,654 |
| Total operating expenses | 113,759 | 80,888 |
| Loss from operations | (69,791) | (64,429) |
| Other income (expense), net | ||
| Interest and investment income, net | 2,314 | 887 |
| Change in fair value of warrant liabilities | (295,413) | (448) |
| Change in fair value of related-party convertible note | (236,625) | (42,582) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — operating income (loss)?
- ImmunityBio, Inc. (IBRX) reported reportable segment — operating income (loss) of -$69.79M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — operating income (loss) changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — operating income (loss) decreased by 8.3% year-over-year, from -$64.43M to -$69.79M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — operating income (loss)?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — operating income (loss) has grown at a -15.9% compound annual growth rate (CAGR), from -$362.25M to -$256.03M.
- What does reportable segment — operating income (loss) mean?
- Measures the profitability or loss generated by a specific business segment after accounting for operating expenses. For clinical-stage companies, this typically reflects the net resource consumption of a specific therapeutic platform or business unit.
Ask your AI about ImmunityBio, Inc.'s reportable segment — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude